Newron Pharmaceuticals S.p.A.
NP5
Rank in Stocks
#16084
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Share Price
$11.18
Last synced: 2026-11-09
Market Cap
$228.56M
Change (1 day)
3.58%
Change (1 year)
-37.51%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Newron Pharmaceuticals S.p.A. (NP5)
Category
Healthcare
Operating Margin for Newron Pharmaceuticals S.p.A. (NP5)
Operating Margin as of November 2026 TTM: -216.76%
According to Newron Pharmaceuticals S.p.A.'s latest financial reports, its current operating margin (TTM) is -216.76%. At the end of 2025 the company had an operating margin of -24.56%.
Operating Margin history for Newron Pharmaceuticals S.p.A. from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -216.76% | 782.57% |
| 2025 | -24.56% | -148.22% |
| 2024 | 50.93% | -139.67% |
| 2023 | -128.40% | -41.18% |
| 2022 | -218.28% | 1.78% |
| 2021 | -214.46% | -37.58% |
| 2020 | -343.59% | 15.71% |
| 2019 | -296.95% | -20.20% |
| 2018 | -372.12% | 1,120.07% |
| 2017 | -30.50% | -86.61% |
| 2016 | -227.85% | -69.32% |
| 2015 | -742.65% | 27.21% |
| 2014 | -583.82% | 165.71% |
| 2013 | -219.72% | 627.07% |
| 2012 | -30.22% | -98.69% |
| 2011 | -2,315.00% | -13.78% |
| 2010 | -2,684.86% | 177.93% |
| 2009 | -966.01% | 107.40% |
| 2008 | -465.78% | 37.00% |
| 2007 | -339.99% | -75.83% |
| 2006 | -1,406.55% | 0.00% |
| 2005 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.18% |
US
|
|
| -149.01% | -99.31% |
US
|
|
| 25.57% | -100.12% |
AU
|
|
| 31.23% | -100.14% |
BE
|
|
| 29.35% | -100.14% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Newron Pharmaceuticals S.p.A.'s operating margin
What is Newron Pharmaceuticals S.p.A.'s operating margin?
Newron Pharmaceuticals S.p.A.'s operating margin is -216.76%, as of Nov 2026.
What was Newron Pharmaceuticals S.p.A.'s operating margin in 2025?
In 2025, Newron Pharmaceuticals S.p.A.'s operating margin was -24.56%, compared with 50.93% in 2024.
How has Newron Pharmaceuticals S.p.A.'s operating margin changed since 2020?
From 2020 to 2025, Newron Pharmaceuticals S.p.A.'s operating margin was highest in 2024 (50.93%) and lowest in 2020 (-343.59%).
How does Newron Pharmaceuticals S.p.A.'s operating margin compare with similar companies?
Newron Pharmaceuticals S.p.A.'s operating margin (-216.76%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.